Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares OutstandingShort-Term Debt repayments
Ratios

HeartSciences (HSCS) EBIAT (2021 - 2026)

HeartSciences filings provide 6 years of EBIAT readings, the most recent being -$2.0 million for Q1 2026.

  • On a quarterly basis, EBIAT rose 21.73% to -$2.0 million in Q1 2026 year-over-year; TTM through Jan 2026 was -$8.5 million, a 0.37% change, with the full-year FY2025 number at -$8.8 million, down 32.7% from a year prior.
  • EBIAT hit -$2.0 million in Q1 2026 for HeartSciences, up from -$2.4 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of -$1.2 million in Q1 2022 to a low of -$2.5 million in Q1 2025.
  • Median EBIAT over the past 5 years was -$1.8 million (2024), compared with a mean of -$1.8 million.
  • Biggest five-year swings in EBIAT: crashed 213.5% in 2022 and later grew 21.73% in 2026.
  • HeartSciences' EBIAT stood at -$1.8 million in 2022, then increased by 3.22% to -$1.7 million in 2023, then dropped by 19.13% to -$2.1 million in 2024, then dropped by 12.86% to -$2.4 million in 2025, then increased by 15.55% to -$2.0 million in 2026.
  • The last three reported values for EBIAT were -$2.0 million (Q1 2026), -$2.4 million (Q4 2025), and -$2.1 million (Q3 2025) per Business Quant data.